Document is current
Any future updates will be listed below
-
Authors
Bury, Alexander G.
Olejnik, Alicja
Tocco, Chiara
Saurat, Nathalie
Stephen, Elezabeth
Hockemeyer, Dirk
Schwamborn, Jens C.
Studer, Lorenz
Mastroberardino, Pier Giorgio
Bolognin, Silvia
Kunath, Tilo
Korolchuk, Viktor I.
Drouin-Ouellet, Janelle
Mortiboys, Heather
-
Funding
Funding for this research was provided by:
Michael J. Fox Foundation for Parkinson's Research (MJFF-022769, MJFF-022769)
- License Information
-
More Information
Article History
Received: 26 June 2025
Accepted: 27 August 2025
First Online: 9 October 2025
Competing interests
: H.M. and E.S. are co-founders and shareholders of Mitotype Precision Labs Limited. H.M. is an inventor on a patent related to bile acids and neurodegenerative diseases. N.S. and L.S. are inventors on a patent filed by MSKCC relating to methods of modulating cellular ageing in neurons. L.S. is also a scientific co-founder and consultant of Bluerock Therapeutics and DaCapo Brainscience. J.C.S. and S.B. are co-founders and shareholders of OrganoTherapeutics SARL. V.I.K. is a Scientific Advisor for Longaevus Technologies. P.G.M. is an inventor on a patent application related to the use of a DNA damage molecular signature in blood for prognostic purposes in Parkinson’s disease. A.G.B., A.O., C.T., D.H., T.K., and J.D.O. declare no competing interests.
